ITOS Stock Analysis
IT
Uncovered
Iteos Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
iTeos Therapeutics, Inc. engages in the development of biopharmaceutical therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 125 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients with cancer. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant. The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its inupadenant, is an adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment. The firm is conducting an open-label multi-arm Phase I/IIa clinical trial of inupadenant in adult cancer patients with advanced solid tumors.